235 related articles for article (PubMed ID: 33481423)
1. Targeted pharmacotherapy of irritable bowel syndrome.
Arokiadoss A; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):214-221. PubMed ID: 33481423
[TBL] [Abstract][Full Text] [Related]
2. New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
[TBL] [Abstract][Full Text] [Related]
3. New treatment targets for the management of irritable bowel syndrome.
Rao S; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):9-14. PubMed ID: 24300740
[TBL] [Abstract][Full Text] [Related]
4. Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome.
Algera JP; Törnblom H; Simrén M
Curr Opin Pharmacol; 2022 Oct; 66():102284. PubMed ID: 36067685
[TBL] [Abstract][Full Text] [Related]
5. Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions.
Grad S; Dumitrascu DL
Dig Dis; 2020; 38(2):122-127. PubMed ID: 31851972
[TBL] [Abstract][Full Text] [Related]
6. Update on Pharmacotherapy for Irritable Bowel Syndrome.
Munjal A; Dedania B; Cash B
Curr Gastroenterol Rep; 2019 Apr; 21(6):25. PubMed ID: 31025114
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
Binienda A; Storr M; Fichna J; Salaga M
Curr Drug Targets; 2018; 19(15):1774-1781. PubMed ID: 29284389
[TBL] [Abstract][Full Text] [Related]
8. The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders.
Vu J; Kushnir V; Cassell B; Gyawali CP; Sayuk GS
Neurogastroenterol Motil; 2014 Sep; 26(9):1323-32. PubMed ID: 25070610
[TBL] [Abstract][Full Text] [Related]
9. The overlap of upper functional gastrointestinal disorders with irritable bowel syndrome in Chinese outpatients: A multicenter study.
Yao X; Yang YS; Cui LH; Sun G; Peng LH; Wang WF; Hyder Q; Zhang XL
J Gastroenterol Hepatol; 2016 Sep; 31(9):1584-93. PubMed ID: 26875585
[TBL] [Abstract][Full Text] [Related]
10. Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy.
Peter J; Fournier C; Keip B; Rittershaus N; Stephanou-Rieser N; Durdevic M; Dejaco C; Michalski M; Moser G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453528
[TBL] [Abstract][Full Text] [Related]
11. Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.
O'Malley D
Exp Physiol; 2019 Jan; 104(1):3-10. PubMed ID: 30444291
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology and quality of life of functional gastrointestinal disorders according to Rome III vs Rome IV criteria: A cross-sectional study in primary care.
Chuah KH; Beh KH; Mahamad Rappek NA; Mahadeva S
J Dig Dis; 2021 Mar; 22(3):159-166. PubMed ID: 33595169
[TBL] [Abstract][Full Text] [Related]
13. A nutritional approach for managing irritable bowel syndrome.
Bhesania N; Cresci GAM
Curr Opin Pediatr; 2017 Oct; 29(5):584-591. PubMed ID: 28737582
[TBL] [Abstract][Full Text] [Related]
14. Marshall and Warren Lecture 2019: A paradigm shift in pathophysiological basis of irritable bowel syndrome and its implication on treatment.
Ghoshal UC
J Gastroenterol Hepatol; 2020 May; 35(5):712-721. PubMed ID: 32162356
[TBL] [Abstract][Full Text] [Related]
15. The spectra, symptom profiles and overlap of Rome III functional gastrointestinal disorders in a tertiary center in South China.
Xiong LS; Shi Q; Gong XR; Cui Y; Chen MH
J Dig Dis; 2014 Oct; 15(10):538-44. PubMed ID: 25102919
[TBL] [Abstract][Full Text] [Related]
16. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.
Fukudo S; Okumura T; Inamori M; Okuyama Y; Kanazawa M; Kamiya T; Sato K; Shiotani A; Naito Y; Fujikawa Y; Hokari R; Masaoka T; Fujimoto K; Kaneko H; Torii A; Matsueda K; Miwa H; Enomoto N; Shimosegawa T; Koike K
J Gastroenterol; 2021 Mar; 56(3):193-217. PubMed ID: 33538894
[TBL] [Abstract][Full Text] [Related]
18. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors.
von Wulffen M; Talley NJ; Hammer J; McMaster J; Rich G; Shah A; Koloski N; Kendall BJ; Jones M; Holtmann G
Dig Dis Sci; 2019 Feb; 64(2):480-486. PubMed ID: 30368683
[TBL] [Abstract][Full Text] [Related]
19. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
[TBL] [Abstract][Full Text] [Related]
20. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
Goodoory VC; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2022 Jul; 56(1):110-120. PubMed ID: 35491477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
